Esperion (ESPR) announced the appointment of Robert Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effective May 29, 2025. In addition, the Company announced that Nicole Vitullo and Antonio Gotto, Jr., M.D., D. Phil. will step down from the board of directors, effective June 1, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion’s Strategic Growth: Phase 3 Expansion and Patent Protection Boost Valuation
- Esperion aligns with U.S. FDA to initiate Phase 3 trials of bempedoic acid
- Esperion’s Promising Future: Strategic Partnerships and Product Innovations Drive Buy Rating
- Sell Rating for Esperion Amidst US Market Underperformance and Competitive Pressures
- Esperion Therapeutics Reports Strong Revenue Growth in 2024
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue